Stay informed with the latest updates for the inheritable blood disorders community.

Industry
Sangamo Announces First Patient Treated in Hemophilia B Gene Therapy Trial
Sangamo Announces First Patient Treated in Hemophilia B Gene Therapy Trial…
Industry
uniQure Announces Initial Data Showing Positive Early Results from Hemophilia B Gene Therapy
uniQure Announces Initial Data Showing Positive Early…
Industry
Bayer receives FDA approval for hemophilia A treatment Jivi®
Bayer receives FDA approval for hemophilia A treatment Jivi®
Industry
Catalyst Updates on Phase 2/3 Trial of Subcutaneous Therapy
Catalyst Updates on Phase 2/3 Trial of Subcutaneous Therapy
Industry
New Medscape Activity Makes the Case for Gene Therapy
Sangamo Reports Positive Preliminary Data from Hemophilia Gene Therapy…
Industry
Spark Reports Progress on Hemophilia A Gene Therapy
Spark Reports Progress on Hemophilia A Gene Therapy
Industry
Court Issues Final Judgement in Shire/Roche Patent Lawsuit
Court Rules on Shire/Roche Preliminary Injunction
Industry
Pfizer Initiates First Stage of Phase 3 Hemophilia B Gene Therapy Trial
Pfizer Initiates First Stage of Phase 3 Hemophilia B Gene Therapy Trial
Industry
Catalyst’s Trial Update Includes Reports of Antibody Responses
Catalyst’s Trial Update Includes Reports of Antibody Responses
Industry
Genentech Patient Foundation Responds to NHF-HFA Letter
HEMLIBRA® Granted Priority Review by FDA
Industry
Bayer Responds to NHF-HFA Joint Statement
FDA Approves New Vial Size for Idelvion®
Industry
uniQure Announces First Hemophilia B Patient Treated in Phase III Gene Therapy Trial
uniQure Reports Successful Delivery of FIX Gene Therapy Despite Antibodies…
Industry
Spark Sees Continued Progress in Hemophilia B Gene Therapy
Spark Sees Continued Progress in Hemophilia B Gene Therapy
Industry
Genentech Announces Positive HEMLIBRA Trial Results
Genentech Announces Positive HEMLIBRA Trial Results
Industry
Genentech Patient Foundation Responds to NHF-HFA Letter
HEMLIBRA® Receives Breakthrough Designation from FDA